Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esmolol in septic shock
NCT03208257Phase 2Unknown
- Start
- Aug 2017
- Primary completion
- Dec 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of esmolol in septic shock. Primary endpoint: Organ-failure-free days at 28 days. Status: unknown.
02
Drugs
esmolol
03
Conditions
septic shock
Beyond the preview
Go deeper on NCT03208257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03208257.